Arcturus Therapeutics Holdings Inc. Share Price
NASDAQ: ARCTArcturus Therapeutics Holdings Inc. Stock Performance
Open N/A | Prev. Close N/A | Circuit Range N/A |
Day Range N/A | Year Range N/A | Volume N/A |
Average Traded N/A |
Arcturus Therapeutics Holdings Inc. Share Price Chart
Arcturus Therapeutics Holdings Inc. Stock Fundamentals & Key Indicators
Market Cap N/A | PE Ratio (TTM) N/A | Dividend Yield N/A |
EPS (TTM) $-2.40 | Revenue (TTM) $82.03M | Return On Equity (TTM) -30.74% |
Profit Margin -80.19% | Debt to Equity 0.17 | Quarterly Earnings Growth YoY N/A |
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings Inc. Historical Returns
| Month | Open | Close | Change % |
|---|
ARCT Share Price FAQs
What is Arcturus Therapeutics Holdings Inc. share price today?
What is the 52 week high and 52 week low of Arcturus Therapeutics Holdings Inc. stock?
Can I buy ARCT shares in India?